A head-to-head trial found that tirzepatide led to significantly greater weight loss and waist reduction than semaglutide in ...

In a nutshell Tirzepatide (Mounjaro) produced 20.2% weight loss compared to semaglutide’s (Wegovy) 13.7% after 72 weeks of ...

The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published ...

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the ...

Participants were randomly assigned either to escalation of dulaglutide to 4.5 mg or maximum tolerated dose (MTD), or to ...

Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.

Like semaglutide, tirzepatide targets the glucagon-like peptide-1 (GLP-1 ... Results were promising, with those taking 5-mg, 10-mg, and 15-mg weekly injections of tirzepatide losing weight ...

Each participant received weekly doses of tirzepatide—either 5 mg, 10 mg, or 15 mg—for three years ... glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide ...

and personalized peptide-based therapies. Whether you're exploring Semaglutide tablets, Tirzepatide injections, or simply want a doctor-supervised, at-home program for sustained fat loss ...

Researchers sought to determine 1-year outcomes in patients being treated with tirzepatide who have atrial fibrillation.

Retatrutide and Tirzepatide represent promising peptides with potential implications in regulating metabolic functions. Their distinct mechanisms of action and possible properties in glycemic ...